A Clinical Research Study for Individuals with Alzheimer’s Disease

Alzheimer’s Disease is a debilitating disease, affecting 1 out of every 8 people over 65 years of age or older. Not only does it impact the individual, but also their family. Further research is needed to help find better treatments.

If you or a loved one has Alzheimer’s Disease, you may be interested to learn about MK-7622-012, a clinical research study now underway at approximately 60 centers across the USA and Canada.

This Alzheimer’s Disease Study is designed to assess whether a new investigational medication, called MK-7622, when given together with the standard Alzheimer’s medication Aricept® (also called donepezil), has an effect on mental abilities impaired by the disease.

Individuals with Alzheimer’s Disease and their caregivers are invited to get involved. An individual may qualify if he or she has a diagnosis of mild to moderate Alzheimer’s Disease:

  • with a history of mental decline over 1 year
  • is 55 to 85 years of age
  • and is on a stable dose of Aricept up to 10 mg a day

Participants must also have a caregiver or family member willing to accompany them to all study appointments, provide feedback on their progress, and ensure they take the study medication as instructed.

Participants with Alzheimer’s Disease will receive investigational medication and study-related care at no charge; health insurance is not necessary.

We invite you to visit www.study4alzheimers.com for general information about Alzheimer’s Disease, why clinical research studies are necessary to develop better treatments and what participants in the MK-7622-012 Study can expect. After reviewing the study information, please take the opportunity to complete a pre-qualification survey to determine if you, or someone you care for who has Alzheimer’s Disease, may be eligible for participation.

For further study information and to see if you or your loved one might be eligible, visit www.study4alzheimers.com. The participating medical center nearest to you will be listed upon successfully passing the short pre-qualification survey.

Taking action today may lead to better treatments tomorrow.